115 results · Page 1 of 5

Swipe the table sideways for more columns.

CitiesCityCountryLinked trials
AntioquiaAntioquiaColombia4
ArmeniaArmeniaColombia13
ArmeniaArmeniaColombia1
ArmeniaArmeniaColombia1
AtlánticoAtlánticoColombia1
BarranquillaBarranquillaColombia82
BarranquillaBarranquillaColombia1
BarranquillaBarranquillaColombia65
BarranquillaBarranquillaColombia3
BelloBelloColombia1
BelloBelloColombia6
BogotaBogotaColombia49
Bogota D.CBogota D.CColombia1
Bogota D.C.Bogota D.C.Colombia1
Bogota DCBogota DCColombia2
Bogota DCBogota DCColombia3
Bogota, D.C.Bogota, D.C.Colombia6
BogotáBogotáColombia1
BogotáBogotáColombia149
BogotáBogotáColombia1
BogotáBogotáColombia1
BogotáBogotáColombia1
BogotáBogotáColombia1
BogotáBogotáColombia90
BogotáBogotáColombia1

498 results · Page 1 of 20

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Natural History of Injectable Permanent Synthetic Filler DiseaseForeign Bodies, Foreign-Body Reaction, Granuloma, Granuloma, Foreign-Body, Pathologic Processes, Pathological Conditions, Signs and Symptoms, injuryRecruitingNot stated2026-10-09NCT07867353
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-10-09NCT07513376
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 2 / Phase 32026-10-09NCT07100080
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, von Willebrand disease (hereditary or acquired), von Willebrand disease 3RecruitingPhase 32026-10-09NCT06998524
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 32026-10-09NCT06878261
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathyRecruitingPhase 32026-10-09NCT06858579
EXtubation Related Complications - the EXTUBE Study (EXTUBE)ExtubationRecruitingNot stated2026-10-09NCT06442930
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusSkin and Connective Tissue Diseases, autoimmune disease, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, subacute cutaneous lupus erythematosus, systemic lupus erythematosusActive, not recruitingPhase 2 / Phase 32026-10-09NCT05531565
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisRecruitingPhase 22026-10-08NCT07415044
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, heart disorder, kidney disorder, kidney failure, nervous system disorder, stroke disorder, urinary system disorder, vascular disorderRecruitingPhase 32026-10-08NCT07241390
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorderActive, not recruitingPhase 32026-10-08NCT07218029
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-10-08NCT07060807
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityArterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorderRecruitingPhase 32026-10-08NCT07037433
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 32026-10-08NCT06925737
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderRecruitingPhase 22026-10-08NCT06226883
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 2 / Phase 32026-10-08NCT05139017
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinibnon-small cell lung carcinomaActive, not recruitingNot stated2026-10-08NCT04764188
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 32026-10-08NCT03678025
Prospective One-Year Evaluation of the Safety and Effectiveness of an Investigator-Developed Rectus Abdominis Plication Technique in AbdominoplastyDisease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RecurrenceRecruitingNot applicable2026-10-07NCT07805915
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-10-07NCT07431827
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaChronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaEnrolling by invitationPhase 32026-10-07NCT07256392
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-10-07NCT07190248
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Heterozygous Familial Hypercholesterolemia (HeFH)RecruitingPhase 2 / Phase 32026-10-07NCT07058077
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinomaRecruitingPhase 32026-10-07NCT06997497
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingPhase 22026-10-07NCT06598943